Alzheimer’s disease is one of the most pressing neurological challenges of our time, with inflammation in the brain increasingly recognized as a major driver of disease progression. In a recent study, researchers explored a compound known as D30—scientifically named (E)-2-(3,4-dihydroxystyryl)-3-hydroxy-4H-pyran-4-one—and found that it could significantly reduce neuroinflammation, clear amyloid-β buildup, and improve memory function in mice. This compound appears to work by regulating galectin-3 expression and modulating the PI3K/AKT/mTOR signaling pathway, both of which play central roles in inflammation and cellular survival.
These findings open up new possibilities for treating Alzheimer’s by shifting the therapeutic focus toward inflammation control and brain cell resilience. While D30 is still in early preclinical testing, its multi-targeted effects make it a compelling candidate for future drug development. As researchers continue to uncover the molecular mechanics of memory loss, interventions like D30 could offer a new path forward—one that addresses both the symptoms and root causes of cognitive decline.
1. The compound (E)-2-(3,4-dihydroxystyryl)-3-hydroxy-4H-pyran-4-one alleviates neuroinflammation and cognitive impairment in a mouse model of Alzheimer’s disease
A novel compound, D30, reduced brain inflammation, cleared amyloid-β, and improved memory in a mouse model of Alzheimer’s disease—likely by regulating galectin-3 and the PI3K/AKT/mTOR pathway.
2. Pharmacological targeting cGAS/STING/NF-κB axis by tryptanthrin induces microglia polarization toward M2 phenotype and promotes functional recovery in a mouse model of spinal cord injury
Tryptanthrin, a plant-derived compound, promotes healing after spinal cord injury by shifting microglia from a harmful (M1) to a protective (M2) state. It works by targeting the cGAS/STING/NF-κB pathway, reducing neuroinflammation and supporting neuron survival in mice.
3. Human neural stem cell–derived extracellular vesicles protect against ischemic stroke by activating the PI3K/AKT/mTOR pathway
Extracellular vesicles from human neural stem cells reduce brain damage after stroke in rats by activating the PI3K/AKT/mTOR pathway—offering a safer, cell-free approach to neurorepair.
If you’d like to stay informed of the latest publications and breakthroughs in neuron regeneration, join our email newsletter to the right (or below on mobile). We send out weekly updates with the latest papers and studies, as well as podcast episodes with the people driving Neuroregenerative breakthroughs.
